Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.32 |
| ▸ | HPGD | P15428 | 2/20 | 0.32 |
| ▸ | CLK4 | Q9HAZ1 | 2/20 | 0.32 |
| ▸ | CDK2 | P24941 | 5/20 | 0.32 |
| ▸ | CDK5 | Q00535 | 4/20 | 0.32 |
| ▸ | CDK7 | P50613 | 4/20 | 0.32 |
| ▸ | CDK5R1 | Q15078 | 3/20 | 0.32 |
| ▸ | CCNT1 | O60563 | 2/20 | 0.32 |
| ▸ | CCNE1 | P24864 | 2/20 | 0.32 |
| ▸ | CDK9 | P50750 | 2/20 | 0.32 |
| ▸ | CCNH | P51946 | 2/20 | 0.32 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.32 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.32 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.31 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.31 |
| ▸ | FAAH | O00519 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11951634 | 0.81 | KDM4E (0.38) | KDM4EHTTALDH1A1CDK2CDK5 | |
| SCHEMBL12913573 | 0.81 | GPR119 (0.37) | KDM4EHTTALDH1A1HPGDCLK4 | |
| SCHEMBL1369575 | 0.79 | KDM4E (0.34) | KDM4EHTTALDH1A1HPGDCLK4 | |
| SCHEMBL20558034 | 0.79 | GPR119 (0.36) | KDM4EHTTALDH1A1CDK2CDK5 | |
| SCHEMBL13153941 | 0.77 | KDM4E (0.56) | KDM4EHTTALDH1A1HPGDCLK4 | |
| SCHEMBL24938786 | 0.76 | KDM4E (0.36) | KDM4EHTTALDH1A1HPGDCLK4 | |
| SCHEMBL11951631 | 0.76 | AHR (0.40) | KDM4ECDK2CDK5CDK7CDK5R1 | |
| SCHEMBL11951643 | 0.73 | CDK7 (0.39) | CDK2CDK5CDK7CDK5R1CCNT1 | |
| SCHEMBL19201115 | 0.73 | KDR (0.44) | KDM4EHTTALDH1A1HPGDCLK4 | |
| SCHEMBL127121 | 0.73 | SMPD3 (0.43) | KDM4EHTTALDH1A1HPGDCLK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110831600-B | Indole AHR inhibitors and uses thereof | 医肯纳肿瘤学公司 | 2023-10-17 | — | — | CN | disclosed |
| US-20230250088-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | NOVARTIS PHARMA AG (CH) | 2023-08-10 | — | — | US | disclosed |
| US-20230250088-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | NOVARTIS PHARMA AG (CH) | 2023-08-10 | — | — | US | disclosed |
| US-20230028336-A1 | INDOLE AHR INHIBITORS AND USES THEREOF | PAHR THERAPEUTICS, INC. | 2023-01-26 | — | — | US | disclosed |
| US-11358969-B2 | Indole AHR inhibitors and uses thereof | Ikena Oncology, Inc. (US) | 2022-06-14 | — | — | US | disclosed |
| US-20200331917-A1 | INDOLE AHR INHIBITORS AND USES THEREOF | PAHR THERAPEUTICS, INC. | 2020-10-22 | — | — | US | disclosed |
| US-10689388-B1 | Indole AHR inhibitors and uses thereof | Ikena Oncology, Inc. (US) | 2020-06-23 | — | — | US | disclosed |
| EP-3612030-A2 | INDOLE AHR INHIBITORS AND USES THEREOF | Kyn Therapeutics (US) | 2020-02-26 | — | — | EP | disclosed |
| US-10570138-B2 | Indole AHR inhibitors and uses thereof | KYN THERAPEUTICS (US) | 2020-02-25 | — | — | US | disclosed |
| CN-110831600-A | Indole AHR inhibitors and uses thereof | 金恩医疗公司 | 2020-02-21 | — | — | CN | disclosed |
| WO-2018195397-A2 | INDOLE AHR INHIBITORS AND USES THEREOF | KYN THERAPEUTICS (US) | 2018-10-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10570138-B2 | Indole AHR inhibitors and uses thereof | AHR, ARNT, IDO1 | KDM4E 923/4885HTT 274/4885ALDH1A1 316/4885 |
| US-11358969-B2 | Indole AHR inhibitors and uses thereof | AHR, ARNT, IDO1 | KDM4E 923/4885HTT 274/4885ALDH1A1 316/4885 |
| US-20200331917-A1 | INDOLE AHR INHIBITORS AND USES THEREOF | AHR, ARNT, IDO1 | KDM4E 923/4885HTT 274/4885ALDH1A1 316/4885 |
| US-10689388-B1 | Indole AHR inhibitors and uses thereof | AHR, ARNT, IDO1 | KDM4E 923/4885HTT 274/4885ALDH1A1 316/4885 |
| US-20230028336-A1 | INDOLE AHR INHIBITORS AND USES THEREOF | AHR, ARNT, IDO1 | KDM4E 923/4885HTT 274/4885ALDH1A1 316/4885 |
| US-20230250088-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | STING1, CGAS, IRF3 | KDM4E 3667/4885HTT 2463/4885ALDH1A1 4633/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.